一、核心结论与销售表现诺诚健华 (688428。SH)发布的2024年报显示,其核心产品奥布替尼全年实现收入10.00亿元,同比增长49.14%,超出市场预期。这一优异表现主要得益于医保覆盖范围的扩大以及差异化适应症布局,例如奥布替尼是国内唯一获批治疗MZL的BTK抑制剂。此外,公司商业化能力的提升和药物良好的疗效及安全性也推动了患者依从性提高,延长了用药时间。二、研发管线进展迅速公司在血液瘤领域...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.